公开(公告)号：US20170369592A1

公开(公告)日：2017-12-28

申请号：US15541998

申请日：2016-01-11

申请人： Mabimmune Diagnostics AG ,  Neurimmune Holding AG ,  University of Zurich

发明人： Chad BROKOPP ,  Jan GRIMM ,  Benoit COMBALUZIER ,  Mareike GOERANSON ,  Christine LOHMANN ,  Simon HOERSTRUP ,  Roger NITSCH

IPC分类号： C07K16/40 ,  G01N33/573 ,  A61K47/68 ,  C12N9/48 ,  C07K16/28 ,  G01N33/574

CPC分类号： C07K16/40 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/485 ,  C12Y304/14005 ,  G01N33/573 ,  G01N33/57492 ,  G01N2333/948 ,  G01N2800/224 ,  G01N2800/226 ,  G01N2800/323 ,  G01N2800/52

摘要： Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

公开(公告)号：US20130266585A1

公开(公告)日：2013-10-10

申请号：US13827673

申请日：2013-03-14

申请人： UNIVERSITY OF ZURICH

发明人： Roger NITSCH ,  Christoph Hock ,  Christoph Esslinger ,  Marlen Knobloch ,  Kathrin Tissot ,  Jan Grimm

IPC分类号： C07K16/00 ,  A61K39/395 ,  A61K45/06

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/6854 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N2800/52

摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.